Hormone replacement therapy and the risk of venous thromboembolism: a population‐based study

@article{Renoux2010HormoneRT,
  title={Hormone replacement therapy and the risk of venous thromboembolism: a population‐based study},
  author={Christel Renoux and Sophie Dell'aniello and Samy Suissa},
  journal={Journal of Thrombosis and Haemostasis},
  year={2010},
  volume={8}
}
Summary.  Background: Hormone replacement therapy (HRT) using oral estrogen alone or combined with a progestogen is associated with an increased risk of venous thromboembolism (VTE) in postmenopausal women. This risk may differ for tibolone and transdermal HRT. Methods: Among the United Kingdom’s General Practice Research Database, we identified the cohort of all women aged 50–79 between 1 January 1987 and 1 March 2008. Using a nested case–control approach, all incident cases of VTE occurring… Expand
Concurrent use of statins and hormone therapy and risk of venous thromboembolism in postmenopausal women: a population-based case-control study
TLDR
Statins could potentially attenuate the increased risk associated with HT combinations of oral estrogens and progestogens, and this observation needs further confirmation in other large cohorts. Expand
Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration
TLDR
The risk of venous thromboembolism (VTE) is higher in users of systemic combined estrogen–progestogen treatment than in Users of estrogen only, and the risk of VTE was lower for women who used local estrogen than among those using oral estrogen only. Expand
Hormone replacement therapy and venous thromboembolism
TLDR
Advanced proteomic and genomic studies may hold promise in the future for better elucidating which HRT users are at highest risk for VTE, acknowledging there is no way to fully mitigate the risk of VTE. Expand
Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases
TLDR
Transdermal treatment was the safest type of hormone replacement therapy when risk of venous thromboembolism was assessed and appears to be underused, with the overwhelming preference still for oral preparations. Expand
Hormone therapy and risk of venous thromboembolism among postmenopausal women.
TLDR
Transdermal estrogens alone or combined with micronized progesterone may represent the safest alternative for women who require postmenopausal hormone therapy. Expand
Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis.
TLDR
VTE risk was increased in postmenopausal women with no previous thromboembolic events using oral HT, and further clinical trials are needed to sort out the impact of different types of progestin and different estrogen doses and administration routes on VTE risk. Expand
Protocol to assess risk of venous thromboembolism associated with use of hormone replacement therapy in real world settings: two nested case-control studies in primary care
TLDR
The proposed nested case-control study aims to investigate the risks associated with different types of HRT, including the effects of duration, length of any gap since last use and method of application for the most common types ofHRT. Expand
Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women
TLDR
Transdermal estrogens may improve substantially the benefit/risk ratio of postmenopausal hormone therapy and should be considered as a safer option, especially for women at high risk for VTE. Expand
Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis
  • P. Scarabin
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2018
TLDR
Clinical findings emphasize the safety advantage of transdermal estrogen combined with progesterone and support the current evidence-based recommendations on HT, especially in women at high VTE risk. Expand
Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy
TLDR
This large matched-cohort study based on real-world data suggests that women receiving transdermal ET have significantly lower incidences of CVD events compared with those receiving oral ET, and that they also incur lower healthcare costs. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Hormone replacement therapy with estradiol and risk of venous thromboembolism--a population-based case-control study.
TLDR
It is concluded that use of HRT containing estradiol was associated with a threefold increased risk of VTE, but this increased risk was restricted to the first year of use. Expand
Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study
TLDR
Oral but not transdermal estrogen is associated with an increased VTE risk, and data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect toThrombotic risk. Expand
Hormone replacement therapy and risk of venous thromboembolism: population based case-control study
TLDR
Current use of hormone replacement therapy was associated with a higher risk of venous thromboembolism, although the risk seemed to be restricted to the first year of use. Expand
Hormone replacement therapy and risk of venous thromboembolism: population based case-control study.
TLDR
Current use of hormone replacement therapy was associated with a higher risk of venous thromboembolism, although the risk seemed to be restricted to the first year of use. Expand
Risk of venous thromboembolism in users of hormone replacement therapy
TLDR
Current HRT use is associated with risk of VTE and the increased risk may be concentrated in new users, which needs to be weighed against the probable benefits of long-term treatment. Expand
Hormone replacement therapy use and the risk of stroke.
TLDR
A case-control study within a cohort of women aged 50-79 without history of stroke, finding no evidence of an elevated risk of stroke associated with the use of tibolone and the small elevated risk with estrogens or estrogens plus progestogen is consistent with that reported in randomised trials. Expand
Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study
TLDR
In contrast to oral estrogen, transdermal estrogen does not confer an additional risk of idiopathic VTE in women with increased BMI, and the safety of transDermal estrogen on thrombotic risk has to be confirmed. Expand
Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe.
TLDR
Current users of hormone replacement therapy had 2.3 times higher risk of venous thromboembolism compared with nonusers, and the increased risk was restricted to the first year of treatment. Expand
Prothrombotic Mutations, Hormone Therapy, and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration
TLDR
In contrast to oral estrogen, transdermal estrogen does not confer additional risk on women who carry a prothrombotic mutation, and the safety of transDermal estrogen has to be confirmed in randomized trials. Expand
Hormone therapy and venous thromboembolism.
  • R. Peverill
  • Medicine
  • Best practice & research. Clinical endocrinology & metabolism
  • 2003
TLDR
Early evidence suggests an interaction of HRT with thrombophilic states such as the factor V Leiden mutation, resulting in a synergistic increase in the risk of VTE. Expand
...
1
2
3
4
5
...